Product Description
STM-01 has proven superior to all other stem cell therapeutics in restoring cardiac function in animals following an induced heart attack, reflecting an ability to halt or reverse the inflammation, apoptosis, and other processes that compromise heart function in this model. The results below compare STM-01 to vehicle (IMDM), cardiosphere-derived cells (CDC), adult MSCs, adult cardiac progenitor cells (BM-MSC), and umbilical cord blood derived MSCs (UCBC). (Sourced from: https://secretometherapeutics.com/pipeline/)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Secretome Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|